Boston Trust Walden Corp Has $43.97 Million Holdings in Halozyme Therapeutics, Inc. $HALO

Key Points

• Boston Trust Walden Corp reduced its holdings in Halozyme Therapeutics by 2.5%, now owning approximately 0.69% of the company, valued at $43.97 million.
• Several analysts have given mixed ratings on Halozyme Therapeutics, with six analysts recommending a "Buy" and others maintaining a "Hold" rating, placing an average price target of $73.00 on the stock.
• Insider selling activity was noted, with Director Bernadette Connaughton and CFO Nicole Labrosse selling shares recently, which may indicate shifting investor sentiment among company executives.

Boston Trust Walden Corp cut its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 2.5% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 845,246 shares of the biopharmaceutical company's stock after selling 21,626 shares during the quarter. Boston Trust Walden Corp owned approximately 0.69% of Halozyme Therapeutics worth $43,970,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Penserra Capital Management LLC acquired a new stake in Halozyme Therapeutics in the first quarter valued at about $125,000. Bessemer Group Inc. boosted its stake in shares of Halozyme Therapeutics by 62.9% during the first quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company's stock valued at $34,000 after purchasing an additional 207 shares in the last quarter. Redhawk Wealth Advisors Inc. boosted its stake in shares of Halozyme Therapeutics by 14.8% during the second quarter. Redhawk Wealth Advisors Inc. now owns 37,419 shares of the biopharmaceutical company's stock valued at $1,947,000 after purchasing an additional 4,827 shares in the last quarter. Intech Investment Management LLC boosted its stake in shares of Halozyme Therapeutics by 9.9% during the first quarter. Intech Investment Management LLC now owns 153,199 shares of the biopharmaceutical company's stock valued at $9,776,000 after purchasing an additional 13,789 shares in the last quarter. Finally, Fifth Third Bancorp boosted its stake in shares of Halozyme Therapeutics by 29.4% during the first quarter. Fifth Third Bancorp now owns 10,017 shares of the biopharmaceutical company's stock valued at $639,000 after purchasing an additional 2,276 shares in the last quarter. 97.79% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on HALO shares. Weiss Ratings raised Halozyme Therapeutics from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Wednesday, October 8th. JMP Securities lifted their price objective on Halozyme Therapeutics from $78.00 to $91.00 and gave the stock a "market outperform" rating in a research note on Wednesday, August 6th. JPMorgan Chase & Co. lifted their price objective on Halozyme Therapeutics from $60.00 to $63.00 and gave the stock a "neutral" rating in a research note on Thursday, August 7th. Zacks Research lowered Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Monday, October 6th. Finally, HC Wainwright lifted their price objective on Halozyme Therapeutics from $85.00 to $90.00 and gave the stock a "buy" rating in a research note on Thursday, October 2nd. Six equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Halozyme Therapeutics currently has an average rating of "Hold" and an average price target of $73.00.

Insiders Place Their Bets

In other news, Director Bernadette Connaughton sold 2,000 shares of the business's stock in a transaction that occurred on Wednesday, October 1st. The stock was sold at an average price of $75.24, for a total transaction of $150,480.00. Following the completion of the sale, the director owned 44,952 shares in the company, valued at $3,382,188.48. The trade was a 4.26% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Nicole Labrosse sold 2,227 shares of the business's stock in a transaction that occurred on Monday, September 22nd. The shares were sold at an average price of $77.95, for a total value of $173,594.65. Following the sale, the chief financial officer owned 22,079 shares of the company's stock, valued at approximately $1,721,058.05. This represents a 9.16% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 108,227 shares of company stock worth $7,779,595. 2.90% of the stock is owned by corporate insiders.

Halozyme Therapeutics Trading Up 2.0%

Shares of HALO stock opened at $66.65 on Wednesday. The company has a market cap of $7.80 billion, a P/E ratio of 15.25, a PEG ratio of 0.35 and a beta of 1.16. The stock has a 50 day simple moving average of $71.30 and a two-hundred day simple moving average of $62.01. The company has a debt-to-equity ratio of 4.54, a quick ratio of 7.01 and a current ratio of 8.36. Halozyme Therapeutics, Inc. has a fifty-two week low of $42.01 and a fifty-two week high of $79.50.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share for the quarter, topping analysts' consensus estimates of $1.23 by $0.31. The business had revenue of $325.72 million during the quarter, compared to the consensus estimate of $282.66 million. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.The firm's revenue for the quarter was up 40.8% on a year-over-year basis. During the same period in the previous year, the company posted $0.91 earnings per share. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. Research analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.